A Wagyu Beef-like Appearance of Hyperpigmentation: A Quiz
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0105Keywords:
psychologic, pigmented, diagnostics, differential diagnosisDownloads
References
Kumarasinghe SPW, Pandya A, Chandran V, Rodrigues M, Dlova NC, Kang HY, et al. A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl’s melanosis. Int J Dermatol 2019; 58: 263–272. DOI: https://doi.org/10.1111/ijd.14189
Tan C. Atlas of pigmentary disorders. In: Springer Nature. Cham 2016.
Shah S, Baskaran N, Vinay K, Bishnoi A, Parsad D, Kumaran MS. Acquired dermal macular hyperpigmentation: an overview of the recent updates. Int J Dermatol 2023; 62: 1447–1457. DOI: https://doi.org/10.1111/ijd.16859
Alsisi GG, Alsisi MH, Alhowaish AK, Alshammari WS. Erythema dyschromicum perstans after adalimumab treatment. Cureus 2022; 14: e32264. DOI: https://doi.org/10.7759/cureus.32264
Mariano M, Donati P, Cameli N, Pigliacelli F, Morrone A, Cristaudo A. Ribociclib-induced erythema dyschromicum perstans (ashy dermatosis)-like pigmentation in a metastatic breast cancer patient. J Breast Cancer 2021; 24: 117–121. DOI: https://doi.org/10.4048/jbc.2021.24.e1
Ransohoff KJ, Pugliese SB, Zaba LC, Rieger KE, Kwong BY. Epidermal growth factor receptor inhibitor therapy-associated erythema dyschromicum perstans-like eruption: a case series. Br J Dermatol 2020; 183: 1130–1132. DOI: https://doi.org/10.1111/bjd.19396
Leung N, Oliveira M, Selim MA, McKinley-Grant L, Lesesky E. Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment. Int J Womens Dermatol 2018; 4: 216–222. DOI: https://doi.org/10.1016/j.ijwd.2018.08.003
Torrelo A, Zaballos P, Colmenero I, Mediero IG, de Prada I, Zambrano A. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol 2005; 19: 422–426. DOI: https://doi.org/10.1111/j.1468-3083.2005.01203.x
Srinivasan D, Gottlieb A. Successful management of erythema dyschromicum perstans following topical ruxolitinib therap. J Drugs Dermatol 2023; 22: 297–299. DOI: https://doi.org/10.36849/JDD.7156
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
